The stocks make news after the bell.
FedEx issued upbeat guidance for its full fiscal year and its shares rose more than 3%. FedEx reported mixed results for its fiscal fourth quarter, with adjusted earnings per share of $6.87 and revenue of $24.39 billion. Earnings per share were expected to be $6.86 by analysts.
After the FDA placed a clinical hold on Sarepta's treatment, the biopharma stock dropped more than 5%. There was an adverse event in one of the studies.
Smith & Wesson's fiscal fourth quarter report showed a year over year decline in revenue and gross margin. The company increased its quarterly divided to 10 cents per share from 8 cents.